MaxCyte, Inc. CFO Transition Announcement
Recently, MaxCyte, Inc. (NASDAQ: MXCT), a pioneering company in cell engineering technologies, has revealed that its Chief Financial Officer, Douglas Swirsky, has decided to leave his role in the first half of 2026. Mr. Swirsky and the management team are in the process of ensuring a smooth transition, with a structured search already underway to find his successor. Until the new CFO is appointed, Swirsky will remain actively involved in his role.
Transitioning Leadership Effectively
Commitment to Smooth Operations
CEO Maher Masoud expressed his gratitude towards Mr. Swirsky for his exceptional service and the significant impact he has had on the company. Masoud commended Swirsky for providing ample notice and the opportunity to ensure a thoughtful transition, indicating that this meticulous planning will facilitate continuity in corporate strategy.
Future Outlook and Company Stability
Maintaining Business Continuity
The leadership transition is not expected to disrupt MaxCyte’s operations or its focus on strategic initiatives. Swirsky will stay on in an advisory role post-transition to guarantee the smooth execution of the company's ongoing projects.
About MaxCyte, Inc.
Advancing Cell-Based Therapeutics
MaxCyte is dedicated to improving cell-engineering processes essential for the discovery and commercialization of advanced cell therapies. Their innovative Flow Electroporation® technology and comprehensive SeQure DX™ gene editing services play a crucial role in enabling researchers worldwide to develop safe and effective therapeutic solutions. With over 25 years in the field, MaxCyte has solidified its reputation as a leader in the cell therapy sector, continuously pushing the boundaries of science and medicine.
Company Contacts
Reaching Out to MaxCyte
For investor inquiries, MaxCyte works with the Gilmartin Group. David Deuchler, CFA, is available at +1 415-937-5400 or via email at ir@maxcyte.com.
Media can connect with Kristen White at Oak Street Communications at 415.608.6060 or via email at kristen@oakstreetcommunications.com.
Frequently Asked Questions
What did MaxCyte announce regarding its CFO?
MaxCyte announced that CFO Douglas Swirsky will transition from his role in the first half of 2026, and a search for his successor is underway.
Will the CFO transition affect operations?
No, the transition is not expected to impact the company's operations or strategic focus.
How long has MaxCyte been in the cell engineering industry?
MaxCyte has over 25 years of experience in the cell engineering sector.
Who is MaxCyte's CEO?
The current CEO of MaxCyte is Maher Masoud.
How can I contact MaxCyte for investor relations?
Investors can reach out to David Deuchler at Gilmartin Group at +1 415-937-5400 or through email at ir@maxcyte.com.